Akums Drugs and Pharmaceuticals Limited — Investor Meet, 15-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Akums Drugs and Pharmaceuticals reported consolidated revenue of ₹1,047 crore for Q2 FY25, a 2% increase quarter-on-quarter but down 12% year-on-year. This decline reflects muted demand, falling API prices impacting revenue, and the absence of significant one-off revenues seen in the prior year. The adjusted EBITDA margin dropped to 12.9% from 15.8% YoY, while adjusted PAT margin improved to 6.4% from 5.2%.

2. **Future Outlook and Growth Drivers**: Management remains optimistic about long-term demand for outsourced drug development and manufacturing amid ongoing investment in R&D and new formulation capabilities. The company is expanding its product pipeline, with significant focus on innovative formulations, including patents for breakthrough therapies aimed at Sickle Cell disease.

3. **Order Book and Operational Updates**: The company has made significant investments in CAPEX, totaling around ₹150 crore in H1 FY25, and has started commercial production at a new injectable facility. Future expansions include a new plant in Jammu, expected to commence production by 2026-27.

4. **Analyst Q&A Insights**: Key discussions focused on volume growth and pricing pressures in the API market, with management acknowledging an 11% decline in volume this quarter. They emphasized that this was largely a cyclical issue rather than a loss of market share. Analysts questioned the timeline for recovery in API margins, with management indicating a stabilization in prices may occur by late FY25.

5. **Market or Regulatory Updates**: No specific regulatory concerns or changes were highlighted, but management emphasized ongoing compliance with evolving market conditions which could impact future growth trajectories.

6. **Strategic Focus Areas**: Akums is channeling resources into global expansion, particularly targeting export markets in Europe and Africa. The commitment to innovation in R&D and entering new therapeutic areas marks a strategic pivot to enhance long-term growth.

7. **Investor Insight**: Given the current financial health, ongoing investment in innovation, and strategic market expansions, there is a constructive outlook for Akums. Aligning with demand recovery and improved API pricing dynamics could make this a potential 'buy' for investors looking for long-term growth in the pharmaceutical sector.